not generalizable to other RCTs. Goal Attainment Scaling (GAS); Global Measures. Clinician Interview-Based Impression of Change plus caregiver input ( CIBIC. interview [CIBIC-plus]). The ADAS- cog, disease assessment in dementia scale, and neuropsychiatric inventory are recorded by supervising site investigator, but . The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC -Plus), is widely used in antidementia drug trials. It comprises Likert scales for.

Author: Kigarr Zulkijin
Country: Mali
Language: English (Spanish)
Genre: Travel
Published (Last): 4 December 2010
Pages: 462
PDF File Size: 6.80 Mb
ePub File Size: 12.63 Mb
ISBN: 316-3-30000-394-4
Downloads: 2482
Price: Free* [*Free Regsitration Required]
Uploader: Meztirisar

To determine whether donepezil is effective and tolerable for Chinese patients with severe AD. Slim J, Wright CC.

Search Our Scientific Publications & Authors

Video Recording Voices of patients, caregivers, and CIBIC plus-J interviewers were recorded, and facial expressions of patients and caregivers were videotaped. Donepezil preserves cognition and cibjc function in patients with severe Alzheimer disease. The kappa statistic in reliability studies: Many clinical and animal studies demonstrate the importance of long-chain polyunsaturated fatty acids LCPUFA in neural development and neurodegeneration.

Dement Geriatr Cogn Disord. We utilized area-under-the-curve AUC analysis to assess six-month cumulative treatment efficacy of memantine-donepezil combination versus component monotherapies on individual clinical domains and on a composite index.

In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. Sixteen outpatients with a diagnosis of FTD were enrolled.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

Patients were randomized to donepezil 10 mg daily or placebo for 24 weeks. To evaluate the additional benefit of combination therapy over monotherapy with either AChEI or memantine. Epub Jun 8. Anticholinergic challenge can induce odor identification impairment that indicates Alzheimer’s disease pathology. In particular, this manuscript will focus on Alzheimer’s disease AD and considerations when dealing with new treatment options.

  HEF4069 PDF

The global severity scales that have been used include: The institutional review board at each site approved the conduct of this study prior to commencement. Am J Occup Ther.

Development of a new rating scale for dementia in the elderly: Expert Opin Pharmacother Apr 6;19 5: Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: In addition, scaoe ethics committee approved the conduct upon request at some sites and their institutional review boards.

To evaluate scael efficacy and safety of memantine in patients with mild to moderate Alzheimer’s disease AD receiving cholinesterase inhibitor ChEI treatment. Page 1 of 3 Next.

A questionnaire survey of family caregivers caring scaoe dementia patients at home was carried out to investigate how the use of these services might affect the information about the patients provided zcale the caregivers. To evaluate efficacy and safety of galantamine for patients with vascular dementia VaD. We examined how this change compared with measures of clinical meaningfulness. Int J Geriatr Psychiatry Jul;23 7: Two galantamine titration regimens in patients switched from donepezil.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

The sites where this method can be conducted are limited, because a sufficiently large room must be available for the videotaping, as well as sufficient time for the videotaping process. This is a secondary analysis of a 12 month open-label study of patients 71 women diagnosed with mild to moderate AD treated with mg of donepezil daily. Howard H Feldman Scae Lane. Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer’s disease AD.



CIBIC-plus Publications | PubFacts

Please scqle our privacy policy. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http: Although this was a multicenter study, the precision of CIBIC plus-J assessment was also likely to be improved, because the total number of raters was decreased to seven central raters, with two raters assessing each patient.

Epub Jan Donepezil ciic been used worldwide for the treatment of severe Alzheimer’s disease AD. Vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease hereinafter, subcortical Vascular cognitive impairment without dementia represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating Vascular cognitive impairment without dementia.

BMC Neurol Aug 30;7: